Projected health impact of post-discharge malaria chemoprevention among children under the age of five years with severe malarial anaemia in Africa: a modelling analysis

Lucy Okell, Titus Kwambai, Aggrey Dhabangi, Carole Khairallah, Thandile Nkosi Gondwe, Andria Mousa, Melf Jakob Kuhl, Robert Opoka, Tim Lucas, Richard Idro

Research output: Contribution to journalArticle


Children recovering from severe malarial anaemia (SMA) remain at high risk of readmission and death after discharge from hospital. However, a recent trial found that post-discharge malaria chemoprevention (PDMC) reduces this risk. We developed a mathematical model describing the daily incidence of uncomplicated and severe malaria requiring readmission among 0-5 year-old children after hospitalised SMA. We fitted the model to a multicentre clinical PDMC trial using Bayesian methods. We then modelled the potential impact of PDMC across malaria-endemic African countries. In the 19 highest-burden countries, we estimate that only 2-5 children need to be given PDMC to prevent one hospitalised malaria episode, and less than 100 to prevent one death. If all hospitalised SMA cases access PDMC, 37,000 (range 16,000-84,000) malariaassociated readmissions could be prevented annually, depending on access to hospital care. We estimate that recurrent SMA post-discharge constitutes 18-29% of all SMA episodes in higher transmission settings.

Original languageUndefined/Unknown
JournalPaediatrics and Child Health, East Africa
Publication statusPublished - 1 Jan 2022

Cite this